Professor Haq will present data from a 21 patient, single arm, multi-centre, multi-national open-label, exploratory clinical trial examining the potential of subcutaneous injections of hyperimmune caprine sera (HICS, AIMSPRO®) as a novel treatment for ALS. He will also present supportive data from a study of the drug in a preclinical animal model of the disease.
The AAN annual meeting is the world’s largest international congress of neurologists and neuroscience professionals.
The title, timing and location of Professor Haq’s presentation are:
Title: The role of stabilized neuropeptides derived from hyperimmune caprine sera (HICS) in motor neuron disease – implications for a novel therapeutic strategy
Presented by: Professor Syed B. Haq, London, England
Session: Emerging Science Poster Presentations – Poster Session 4
P04.268
Date: Wednesday, March 20, 2013
Presentation time: 7:30 am to 12:00 pm PDT
The abstract will be available for download on Daval International’s website by March 21, 2013, 07:00 am GMT, see www.davalinternational.com
For further information please contact:
Daval International Ltd
James Shotton +1 303 588 5881 or +44 (0)7739 648401
Chief Executive
NM Rothschild
Julian Hudson +44 (0) 20 7280 5000
FTI Consulting
Julia Phillips / Simon Conway +44 (0)20 7831 3113
About AIMSPRO®
AIMSPRO® (Hyperimmune Caprine Sera, HICS) is a proprietary, purified, protein–multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of immune diseases where regulation and stabilisation of the immune system is required. It is believed that the drug has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and is also available in Australia under Categories A and B of the TGA's Special Access Scheme.
About Daval International Limited
Daval International Limited is an emerging life sciences company focused on the development of novel treatments for serious unmet medical needs through a combination of innovation, dedication, skilled science, entrepreneurship and partnership. From its inception in 2000, the management team of Daval have had a vision of making available effective treatments that noticeably improve the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.
